犬膀胱结石的诊断与治疗

对1例精神沉郁、排尿困难、疑似膀胱结石的京巴犬进行X光诊断并及时给与手术治疗。结果表明,X光检测对犬膀胱结石的确诊具有十分重要的临床学诊断意义,对于单纯性膀胱结石进行手术治疗的效果是确切的,术后抗生素治疗和及时补液也十分关键。     

貂,貉,犬病毒性肠炎快速诊断试剂的研究

用金黄葡萄球菌Ａ蛋白（ＳＰＡ）协同凝集方法（ＣｏＡ）对貂、貉、犬病毒性肠炎快速诊断的试剂进行了制备，确定了制备。艺及该制剂的标准操作程序。本制剂特异性强，不与健康动物的组织及其他几种病毒病（犬瘟热、犬传染性肝炎、狂犬病等）发生交叉凝集反应，灵敏度高，通过该制剂ＣｏＡ法与ＨＡ－ＨＩ法比较结果比现行的貂、貉、犬病毒性肠炎ＨＡ－ＨＩ诊断方法检出率高出３０％，同时具有微量、操作简便、易掌握、快速等特点，可在３～５ｍｉｎ获得诊断结果。     

Thyroid Hormone Concentrations In Critically III Canine Intensive Care Patients

Alterations in thyroid indices in critically ill dogs were studied retrospectively to determine the incidence of the euthyroid sick syndrome and to assess its prognostic relevance to survival. Sixty-seven dogs were classified as euthyroid bases on a TSH stimulation test. Forty-one of 67 (61%) of the euthyroid dogs had low baseline serum T₄ concentrations (<1.5 ug/dl) and 38 of 67 (56%) of the euthyroid dogs had low baseline serum T₃ concentrations (<75 ng/dl). There was no significant difference between either the baseline or the post-stimulation serum T₄ concentrations when values of dogs that survived were compared with those that died. There was, however, a significant difference (P<0.05) between both the baseline and the post-stimulation values for T3 when survivors (100.3± 81 ng/dl, 143± 66 ng/dl) and non-survivors (64.2 ± 17.1 ng/dl, 96.6 ± 38.3 ng/dl) were compared. The euthyroid sick syndrome occurs commonly in critically ill dogs. Further, the extent of depression of serum concentrations of T₃ may be correlated to mortality.     

感染性犬2型腺病毒全基因组克隆及鉴定

以犬 2型腺病毒 (canine adenovirus type- 2 ,CAV- 2 )自然弱毒株 YCA18基因组 DNA为模板 ,经 PCR扩增分别获得其双链两末端 10 13bp(U)和 972 bp(D)的 DNA序列 ,以首尾相接方式克隆入载体 p Poly2 ,获得重组质粒p Poly2 - UD。以 Hind 和 Bst B 双酶切 p Poly2 - UD,回收含载体和部分 U、D的大片段并与 CAV- 2 DNA共转化感受态 E.coli Sure TM,经菌体内同源重组 ,获得含有 CAV- 2全基因组序列的重组质粒 p Poly2 - CAV- 2。后者以 Cla 和 Asc 双酶切 ,释放 CAV- 2全基因组 ,通过脂质体介导转染 MDCK细胞 ,盲传 3代后重复转染 1次 ,4d后 ,出现腺病毒典型病变。细胞上清血凝效价为 1∶ 6 40 ,并可被 CAV- 2抗血清有效抑制。以上结果表明 ,本研究获得了具有感染性的CAV- 2全基因组重组质粒 ,为以 CAV- 2作为重组疫苗载体的系列研究奠定了重要基础。     

CANINE HIP DYSPLASIA

It is the purpose of this study to call attention to new bone production that often occurs early in the sequence of pathological changes associated with canine hip dysplasia. New bone production extending to bony remodeling, as well as femoral head subluxation, both occur in the sequence of pathologic changes associated with canine hip dysplasia. Subluxation is considered primary, while osteoarthrosis is a secondary feature, and both are used in the diagnosis of canine hip dysplasia. This report concerns the significance of the presence of a solitary bony osteophyte, or spur, that is frequently evident on the caudal aspect of the femoral neck as viewed on the conventional ventrodorsal projection. This report utilizes findings from pelvic radiographs of 605 dogs (five breeds). There was a greater frequency (54%)of this bony change in cases diagnosed radiographically as dysplastic than in cases diagnosed as normal(15%).Thus, it is suggested that this minimal radiographic change can be used as an indicator of early canine hip dysplasia, especially in the absence of subluxation of the femoral head.     

The Effects of Essential Fatty Acid Supplementation on Intradermal Test Reactivity in Atopic Dogs: a Preliminary Study

Abstract— Twenty-one perennially affected atopic dogs with previous intradermal test reactivity to two or more environmental allergens were retested while receiving either a combination of evening primrose oil and fish oil (EfaVet Regular, Efamol Vet) or a concentrated supplement containing gammalinolenic acid and eicosapentaenoic acid (HGF capsules). Significant differences in the mean number of positive reactions before and during therapy were not found. In addition, the mean histamine, Dermatophagoides pteronyssinus and housedust wheal diameters before and during therapy were not significantly different. However, the mean human dander wheal diameter was significantly reduced (P < 0.05) at the second test, and the mean Dermatophagoides farinae wheal diameter was significantly reduced (P < 0.05) in a group of seven dogs which had received long-term essential fatty acid supplementation with HGF capsules. These results indicate that essential fatty acid supplementation does not abrogate but may reduce intradermal test reactivity in atopic dogs. Résumé— Vingt et un chiens atopiques, présentant des symptômes non saisonniers, ayant eu des tests cutanés positifs à au moins un pneumallergène ont été testés alors qu'ils recevaient une association d'huile d'onagre et d'huile de poisson (Efa Vet Regular, Efamol Vet) ou un supplément concentré d'acides gammalinolénique et éicosapentaénoique (capsules HGF). Aucune différence significative dans le nombre moyen de réactions positives avant et après traitement n'a été observée. En outre les diamètres moyens des réactions à l'histamine. Dermatophagoïdes pteronyssinus et la poussère de maison avant et après traitement n'étaient pas significativement différents. Toutefois, le diamètre moyen des réactions aux squames humaines étaient significativement réduits (P < 0,05) lors du second test, et le diamètre moyen des réactions àDermatophagoïdes farinaeétait significativement réduit (P < 0,05) dans un groupe de sept chiens ayant reçu une supplémentation à long terme de capsules HGF. Ces résultate montrent qu'une supplementation en acides gras essentiel n'anihile pas les tests cutanés mais peu modérer la réactivité cutanée chez certains chiens atopiques. Resumen Veintiún perros atópicos de tipo estacional que presentaban reactividad positiva en la prueba de inyacciones intradérmicas con respecto a dos o más alergenos ambientales, fueron sometidos a una segunda prueba recibiendo simultáneamente una combinación de aceite de Evening Primrose y aceite de pescado (Efa Vet Regular, Efamol Vet) o un concentrado que contenía ácidos gammalinoleico y ecosapentanoico (HGF cápsulas). No se encontraron diferencias significativas en la media de las reacciones positivas antes y después de la medicación. Tampoco se encontraron diferencias significativas entre las medidas del diámetro de la roncha producida por la histamina, el Dermatophagoides pteronyssinus y el alergeno del polvo. Sin embargo, la media del diámetro producido por el alergeno de la caspa humana se vió considerablemente reducida en el segundo test (P < 0.05), así como la del Dermatophagoides farinae (P < 0.05) en un grupo de siete perros los cuales recibieron suplementación con ácidos grasos esenciales a largo plato con HGF cápsulas. Éstos resultados indican que el uso de ácidos grasos esenciales no produce supresión de las reacciones positivas del test intradérmico en perros atópicos, pero sí de las mismas.     

Plasma pro-opiomelanocortin, pro-adrenocorticotropin hormone, and pituitary adenoma size in dogs with Cushing's disease

It is difficult to predict the size of pituitary corticotroph tumors in dogs with Cushing's disease (pituitary-dependent hyperadrenocorticism [PDH]) without pituitary imaging techniques. The purpose of this study was to examine the relationship between plasma adrenocorticotropin hormone (ACTH) precursor concentration and pituitary size in dogs with Cushing's disease. Plasma concentrations of ACTH precursors (pro-opiomelanocortin [POMC]/pro-ACTH) and pituitary tumor height/brain area were measured in 36 dogs with pituitary corticotroph adenomas of various sizes. There was a correlation between tumor size (measured as the pituitary tumor height/brain area ratio [P/B]) and POMC/pro-ACTH concentration (r = .70; P < .0001). Dogs with P/B > or = 0.40 x 10(-2) mm(-1) had higher concentrations of ACTH precursors than dogs with P/B < 0.40 x 10(-2) mm(-1) (median concentration 85 pmol/L, range 15-1,350 pmol/L, n = 14 versus 15 pmol/L, range 15-108 pmol/L, n = 22; P < .0001). With a threshold of 35 pmol/L of POMC/pro-ACTH concentration, the estimated sensitivity and specificity of the kit were 93% (95% confidence interval [CI], 79-100%) and 86% (95% CI, 73-100%), respectively. We interpret these data as indicating that measurement of POMC and pro-ACTH might be of value in the characterization of tumor size in dogs with Cushing's disease. Low POMC/pro-ACTH concentrations make it unlikely that a large pituitary tumor exists in dogs with PDH.     

Evaluation of intravenous pamidronate administration in 33 cancer-bearing dogs with primary or secondary bone involvement

The purpose of this study was to evaluate the clinical safety of pamidronate when administered at a mean dosage of 1.0 mg/kg IV q28d in 33 tumor-bearing dogs. Biochemical tests of renal function were evaluated before each successive pamidronate treatment. Of 33 dogs treated with pamidronate, 1 dog had clinically relevant increases in serum creatinine and blood urea nitrogen concentrations. The biologic activity of IV pamidronate was assessed prospectively in 10 dogs with appendicular osteosarcoma and was assessed on reductions in urine N-telopeptide excretion (P = .042) and enhanced bone mineral density of the primary tumor measured with dual-energy x-ray absorptiometry (P = .024). Additionally, in these 10 dogs, pamidronate's therapeutic activity was supported by subjective improvement in pain control in 4 of the 10 dogs treated. IV pamidronate appears clinically safe in tumor-bearing dogs and may possess modest biologic activity for managing neoplastic complications associated with pathologic bone resorption.     

Does l‐Asparaginase Influence Efficacy or Toxicity When Added to a Standard CHOP Protocol for Dogs with Lymphoma?

The purpose of this study was to evaluate response rates, 1st remission duration (FRD), and toxicity in dogs with previously untreated lymphoma receiving an identical CHOP-based combination chemotherapy protocol with or without L-asparaginase (LASP). One hundred fifteen dogs with lymphoma were scheduled to receive an identical CHOP-based chemotherapy protocol that included L-ASP. However, because of manufacturer-imposed random rationing, 31 dogs did not receive L-ASP as scheduled. The 2 treatment groups were statistically similar with respect to signalment and presence of historical negative prognostic factors. No difference was observed in the median FRD whether dogs did or did not receive L-ASP (206 versus 217 days, respectively; P = .67). No difference was observed in the median overall survival times between dogs receiving or not receiving L-ASP (310 versus 308 days, respectively; P = .84). No statistical difference was observed with respect to overall response rate between dogs that did or did not receive L-ASP (89.3% versus 87.1%, respectively; P = .75). Complete response rates between the groups also were no different (83.3% and 77.4% for L-ASP and non-L-ASP groups, respectively; P = .59). Prevalence of toxicity (neutropenia, diarrhea, or vomiting) and treatment delays (P = .80) also were similar between groups. The results of this study suggest that exclusion of L-ASP in this multidrug protocol does not significantly impact outcome. Therefore, it may be more appropriate to reserve the use of L-ASP for treating relapse in dogs with lymphoma that have failed induction therapy.